CFD: A Novel Biomarker for Detecting and Monitoring Disease.
Non-invasive insights into cell damage to support better clinical decision-making.
Born from Care,
Shaped by Science
CFD® measures cell-free DNA in blood, a marker of how much cell damage is happening in the body. It gives veterinarians a clear, fast way to detect hidden disease, gauge severity, and track treatment progress, from emergencies to long-term care.
World-Class Expertise
A blend of science and commercial strategy, our team includes alumni of the University of Cambridge, the Wellcome Sanger Institute, the University of Helsinki, the Karolinska Institutet, Thermo Fisher, and multiple high-impact entrepreneurial ventures.
Unmatched Data Foundation
DeepScan has built one of the world's largest cfDNA databanks in dogs, with over 5,000 samples analyzed — providing unparalleled insights into canine health at the cellular level.
Research Partnerships
Ongoing collaborations with leading European hospitals and universities ensure our science stays at the cutting edge of veterinary diagnostics and translational medicine.
Clinical Advisory Board
Guided by a world-class clinical advisory board, including the Mars Chair of Oncology Board and 10+ leading oncologists across Europe.
Research Partners
Collaborating with leading veterinary institutions
Clinical Advisory Board
Our advisory board of leading veterinary oncologists guides the clinical development and application of the CFD® biomarker
Commercial Users
Veterinary clinics using CFD® in clinical practice
How to Use the CFD® Biomarker
Clinical Assessment
When you suspect something is wrong, CFD® levels help confirm or rule out underlying cellular damage and guide diagnostic decisions.
Treatment Monitoring
Track CFD® trends over time to assess treatment effectiveness and adjust protocols based on cellular response.
Annual Checkups
Preventative care through regular CFD® monitoring (annually or bi-annually) to detect rising levels early—like tracking blood pressure, but with insight into cell destruction.
Clinical Applications of the CFD® Biomarker
Acute Cases
CFD® Score Correlates Directly with Severity
Use to stratify patients by severity and guide urgent treatment decisions.
Immediate Results Needed
CFD® Point-of-Care (POC) necessary for real-time clinical decisions.
Use Cases:
- Internal bleeding
- Organ failure (single/multiple)
- Critical care severity assessment
Primary Users: Hospitals / Large clinics with ER / ICU facilities
Chronic Cases
CFD® Trend Correlates with Disease Progression
Monitor steep/mild curves vs stable trends to assess disease trajectory.
Use Cases:
- Disease detection (cancer, chronic disease, systemic inflammation)
- Treatment monitoring (success vs stable vs relapse)
- Mass assessment (benign vs malignant via initial level + serial sampling trend)
Primary Users: All veterinary clinics for routine and specialized care
Why the CFD® Biomarker is Essential for Comprehensive Care
The CFD® biomarker works hand-in-hand with traditional biomarkers (such as CRP) to provide a comprehensive picture of your patient's health. By measuring cfDNA levels, veterinarians gain insights into cellular changes happening in the background before they appear as clinical symptoms or abnormalities in routine blood work panels.
Non-Invasive Alternative to Invasive Procedures
The CFD® biomarker provides valuable information about cellular health through a simple blood draw, making it a non-invasive alternative to tissue biopsies or expensive imaging solutions, especially when additional information is needed to confirm a health issue.
Proactive Precision Healthcare
Combining cfDNA with traditional biomarkers (such as CRP) enables veterinarians to detect a wide range of conditions early, from mild inflammation to more serious diseases. This approach supports proactive, personalized care for each dog's unique needs, helping veterinarians make timely, accurate treatment decisions.
Enhanced Diagnostic Clarity
When cfDNA levels are interpreted together with CRP, they reveal a more complete picture of your dog's health. Low cfDNA and low CRP indicate health, while high cfDNA and low CRP may point to early or hidden diseases that might otherwise go unnoticed, such as early-stage cancer or organ damage.
Integrating cfDNA and CRP levels provides veterinarians with a powerful tool for understanding health in a nuanced way, empowering them to address potential issues earlier and improve outcomes with a more targeted approach.
How Clinics Use CFD®
Add CFD® to Blood Work Panel
When drawing blood for routine panels (CBC, chemistry), collect an additional 1 ml EDTA plasma and freeze.
Ship Samples Weekly
Batch frozen samples and send via provided shipping materials. Our logistics partner handles pickup and delivery.
Receive CFD® Scores & Reports
Access detailed results through our secure veterinary portal with individualized reference ranges and clinical interpretation.
Interpret with Clinical Context
Combine CFD® levels with other bloodwork markers (CRP, organ values) for comprehensive diagnostic insights.
Track Trends Over Time
Serial CFD® measurements reveal disease progression or treatment response, critical for managing chronic conditions and cancer.
Communicate Results to Clients
Use our clear, owner-friendly reports to explain findings and recommend proactive care plans that build trust and compliance.
Technical Specifications
| Parameter | Specification |
|---|---|
Sample Type | 3ml blood |
Reference Range | Personalised by breed, age, sex, and neutering status |
Validation | Over 5,000 samples across multiple breeds, ages, and clinical conditions |
Turnaround Time | 2-7 business days |
Frequently Asked Questions
What is the DeepScan CFD® marker and how does it work?
CFD® is measured from circulating cell-free DNA (cfDNA) in blood. cfDNA is released from damaged or dying cells; elevated CFD® levels correlate with cell destruction in the body. That signal helps veterinarians assess disease severity, occult disease, and treatment response—from acute crises to chronic care.
What's the difference between the CFD® marker and traditional blood markers like CRP?
CRP and similar markers flag inflammation. CFD® specifically reflects cell destruction via cfDNA. Used together, they paint a fuller picture: low cfDNA + low CRP suggests health, while high cfDNA + low CRP may indicate early or hidden disease such as early-stage cancer or organ injury.
How is CFD® measured? Is it invasive?
CFD® is measured from a simple, non-invasive blood draw—the same as routine blood work. We quantify cfDNA in EDTA plasma with molecular methods. No tissue biopsies or invasive procedures are required.
What should I do if CFD® results are elevated?
Elevated CFD® means increased cell destruction and deserves clinical follow-up. Reports include the CFD® score, reference ranges, and interpretation guidance. A follow-up sample in 2–3 weeks helps determine whether cfDNA is falling, stable, or rising. Next steps depend on the case—from urgent stabilization to staged diagnostics or therapy monitoring.
